Clinical Trial Update: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tamibarotene plus azacitidine in newly diagnosed RARA-positive higher-risk myelodysplastic syndromes was terminated; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Tamibarotene (tamibarotene)

Snippet

Sponsor: Syros Pharmaceuticals | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: TERMINATED | Results posted: 2025-04-10